Humana shares surge on 2027 Medicare rate boost; UNH, CVS rally

CMS finalized a 2.48% Medicare Advantage payment rate increase for 2027, projected to add over $13 billion in Medicare Advantage payments and affect more than $500 billion of private-plan flows; Humana shares rose 5.4% and peers also gained. CMS will keep the 2024 MA risk-adjustment model for 2027, exclude diagnosis data from unlinked chart reviews (except for beneficiaries who switch plans) starting 2027, and updated Part D risk adjustment to reflect Inflation Reduction Act changes — effects larger for plans relying on unlinked chart reviews.

Analysis

CMS’s calibration of Medicare Advantage/Part D payments is acting like a de-risking event for large, diversified MA managers while simultaneously raising the bar on operational execution. The immediate market reaction understates the heterogeneity in coding exposure: firms with conservative coding and vertically integrated PBM/rebate capture will convert the policy tailwind into durable margin and capital return optionality, while high-coding-intensity operators face asymmetric downside as a structural revenue source is curtailed.

The coding-rule change is a multi-year earnings re-weighting, not a one-off bump — it reduces pay-for-coding arbitrage and increases the importance of underlying medical-loss performance and network design. That shifts competitive dynamics toward insurers who can lower unit medical cost via care management, provider risk arrangements, and formulary control; it also raises the strategic value of PBM assets and narrow-network MA products.

Part D model updates tied to drug-pricing mechanics create a second-order winners list: plan sponsors that can micromanage specialty spend and steer utilization will extract incremental margin, while single-product pharma and mid-cap biologics with heavy Medicare exposure face tougher reimbursement dynamics. Expect these effects to show up in guidance revisions over the next 2–4 quarters as managements re-forecast 2027 enrollment and margin mix.

Risk profile: political/regulatory reversal is the largest tail (election cycle and litigation could re-open models), and coding/accounting audits could create headline volatility in the near term. Tradeable window is 3–12 months; trades should be sized for event risk and monitored for CMS clarifications and insurer disclosure on coding intensity in upcoming earnings calls.

Key Decisions for Investors

• Long HUM (Humana) — size 1.0–1.5% NAV, 6–12 month horizon. Rationale: best-in-class MA franchise + lower coding reliance; target 25–30% upside, protect with 10% stop. Risk: 12–18% draw if political/regulatory reversal or higher utilization surprises.
• Unhedged call-spread on UNH (UnitedHealth) — buy 9-month 5% ITM / sell 25% OTM call spread, size 0.75% NAV. Rationale: capture re-rating of integrated insurer with PBM leverage while capping premium; target 2.5–3x payoff, max loss = premium (~1x). Monitor earnings for coding commentary.
• Pair trade: Long CVS (CVS) / Short MOH (Molina) — equal-dollar, total net exposure 2.0% NAV, 6–12 month horizon. Rationale: CVS benefits from PBM and diversified revenue; Molina is more exposed to margin volatility from risk-adjustment and coding shifts. Target asymmetric return: CVS +20–30%, MOH -15–25%; cut both at 12% stop.
• Tail hedge and monitoring: Buy 6–9 month puts on a small-cap MA basket (example proxy: MOH) sized 0.5% NAV to protect against rapid policy reversal or audit headlines. If CMS provides favorable follow-ups or insurers report conservative coding, consider taking profits and redeploying into long-large-cap insurers.